News | October 27, 2021
Cipla consolidated net profit at Rs 711.36 cr. in Q2FY22
Cipla has reported consolidated financial results for the period ended September 30, 2021
Cipla has reported consolidated financial results for the period ended September 30, 2021
FDI increased 98% year on year in 2020 and pharma exports grew by 18% in the last financial year
Filing marks first protein-based vaccine submitted to MHRA for authorization
Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders
Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor programme
First anticipated spinout from the alliance, Circle Therapeutics, to develop novel muscle stem cell therapies for a variety of skeletal muscle disorders
Harvard Medical School will deliver the first customized program, ‘Accelerate’, to create the next generation of leading experts in clinical development and medical affairs
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the U.S. Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE)
The company plans to expand its portfolio in regulated markets aggressively
Subscribe To Our Newsletter & Stay Updated
